Literature DB >> 16627556

Hereditary hemochromatosis: genetic complexity and new diagnostic approaches.

Dorine W Swinkels1, Mirian C H Janssen, Jürgen Bergmans, Joannes J M Marx.   

Abstract

Since the discovery of the hemochromatosis gene (HFE) in 1996, several novel gene defects have been detected, explaining the mechanism and diversity of iron-overload diseases. At least 4 main types of hereditary hemochromatosis (HH) have been identified. Surprisingly, genes involved in HH encode for proteins that all affect pathways centered around liver hepcidin synthesis and its interaction with ferroportin, an iron exporter in enterocytes and macrophages. Hepcidin concentrations in urine negatively correlate with the severity of HH. Cytokine-mediated increases in hepcidin appear to be an important causative factor in anemia of inflammation, which is characterized by sequestration of iron in the macrophage system. For clinicians, the challenge is now to diagnose HH before irreversible damage develops and, at the same time, to distinguish progressive iron overload from increasingly common diseases with only moderately increased body iron stores, such as the metabolic syndrome. Understanding the molecular regulation of iron homeostasis may be helpful in designing innovative and reliable DNA and protein tests for diagnosis. Subsequently, evidence-based diagnostic strategies must be developed, using both conventional and innovative laboratory tests, to differentiate between the various causes of distortions of iron metabolism. This review describes new insights in mechanisms of iron overload, which are needed to understand new developments in diagnostic medicine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627556     DOI: 10.1373/clinchem.2006.068684

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  21 in total

1.  Need for early recognition and therapeutic guidelines of congenital sideroblastic anaemia.

Authors:  M L H Cuijpers; D J van Spronsen; P Muus; B C J Hamel; D W Swinkels
Journal:  Int J Hematol       Date:  2011-06-08       Impact factor: 2.490

2.  Novel observations in hereditary hemochromatosis: potential implications for clinical strategies.

Authors:  Dorine W Swinkels; Robert E Fleming
Journal:  Haematologica       Date:  2011-04       Impact factor: 9.941

3.  Design and Rationale for the Study of Changes in Iron and Atherosclerosis Risk in Perimenopause.

Authors:  Georgeta Mihai; Xin He; Xiaolan Zhang; Beth McCarthy; Tam Tran; Michael Pennell; Jessica Blank; Orlando P Simonetti; Rebecca D Jackson; Subha V Raman
Journal:  J Clin Exp Cardiolog       Date:  2011

4.  Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method.

Authors:  Sun-Il Hwang; Yong-Yook Lee; Jung-Ok Park; H James Norton; Elene Clemens; Laura W Schrum; Herbert L Bonkovsky
Journal:  Clin Chim Acta       Date:  2011-08-16       Impact factor: 3.786

5.  Iron Overload (with Attention to Genetic Testing and Diagnosis/Management of HFE Wild Type Patients).

Authors:  Narendra Siddaiah; Kris V Kowdley
Journal:  Curr Treat Options Gastroenterol       Date:  2006

Review 6.  Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease.

Authors:  Qurat-ul-ain Jelani; Stuart D Katz
Journal:  Cardiol Rev       Date:  2010 Sep-Oct       Impact factor: 2.644

7.  Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist.

Authors:  Marcel van Deuren; Joyce J C Kroot; Dorine W Swinkels
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 8.  Iron metabolism in the pathogenesis of iron-induced kidney injury.

Authors:  A M F Martines; R Masereeuw; H Tjalsma; J G Hoenderop; J F M Wetzels; D W Swinkels
Journal:  Nat Rev Nephrol       Date:  2013-05-14       Impact factor: 28.314

9.  Non-HFE hemochromatosis.

Authors:  Paulo Caleb Júnior de Lima Santos; Carla Luana Dinardo; Rodolfo Delfini Cançado; Isolmar Tadeu Schettert; José Eduardo Krieger; Alexandre Costa Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

10.  Neogenin inhibits HJV secretion and regulates BMP-induced hepcidin expression and iron homeostasis.

Authors:  Dae-Hoon Lee; Dai-Hoon Lee; Li-Juan Zhou; Li-Juau Zhou; Zheng Zhou; Jian-Xin Xie; Jiau-Xiu Xie; Ji-Ung Jung; Yu Liu; Cai-Xia Xi; Lin Mei; Wen-Cheng Xiong
Journal:  Blood       Date:  2010-01-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.